Dans quelle mesure l'HbA1c permet de prévoir le risque des complications de microangiopathie dans le diabète ?

Glycated hemoglobin (HbA1c) is an imperfect measure of the average of blood glucose; it admits other causes of variability, some of which are known but inaccessible to routine exploration, other causes of variability are unknown. Despite these shortcomings, long-term data from the Diabetes Control and Complications Trial (DCCT) indicate that HbA1c, and more importantly the glycemic load, as assessed by the product of HbA1c by time of exposure, is a powerful marker of the risk of microangiopathy in diabetes.